NCT06984718View on ClinicalTrials.gov

A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 25, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

June 30, 2027

Conditions
HCCHepatocellular Carcinoma
Interventions
BIOLOGICAL

AK104+lenvatinib

Subjects will receive AK104+lenvatinib until disease progression

DRUG

lenvatinib

Subjects will receive lenvatinib until disease progression

Sponsors

Lead Sponsor

Akeso
All Listed Sponsors
lead

Akeso

INDUSTRY

NCT06984718 - A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC | Biotech Hunter | Biotech Hunter